ACKNOWLEDGMENTS
The author acknowledges the technical and editorial assistance over the years provided by The Upjohn Company biomedical staff, especially Sally Boukma. Study 2 was done in collaboration with J. P. Feighner, M.D.; L. F. Fabre, M.D.; K. Rickels, M.D.; and W. T. Smith, M.D. Study 3 assistance was provided by S. G. Thein, Jr., Ph.D. Parts of the text describing Study 2 were reproduced with permission from JAMA, June 10, 1983, vol. 249, pp. 3059-3063, © 1983, American Medical Association.
REFERENCES
1. Abernethy, D. R., Greenblatt, D. J., Divoll, M., and Shader, R. I. (1983): Pharmacokinetics of alprazolam. J. Clin. Psychiatry, 44:45-47. 2. Aden, G. ะก (1982): A Biomedical Approach to the Classification, Diagnosis, and Treatment of Anxiety. Upjohn Company Monograph, pp. 28-35. 3. Aden, G. C. (1983): Alprazolam in clinically anxious patients with depressed mood. /. Clin. Psychiatry, 44:22-24. 4. Aden, G. C, and Thein, S. G, Jr. (1980): Alprazolam compared to diazepam and placebo in the treatment of anxiety. J. Clin. Psychiatry, 41:245-248. 5. Dawson, G. W., Jue, S. G, and Brogden, R. N. (1984): Alprazolam—A review of its psycho-dynamic properties and efficacy in the treatment of anxiety and depression. Drugs, 27:132-147. 6. Feighner, J. P., Aden, G. C, Fabre, L. F., Rickels, K., and Smith, W. T. (1983): Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA, 249:3057-3064. 7. Hamilton, M. (1967): Development of a rating scale for primary depressive illness. Br. J. Clin. Psychol., 6:278-296. 8. Sheehan, D. V. (1986): Tricyclic antidepressants in the treatment of panic and anxiety disorders. Psychosomatics, 27:10-16.
Anxious Depression: Assessment and Treatment, edited by G. Racagni and E. Smeraldi. Raven Press, New York © 1987.